Table 1

Patients’ characteristics at baseline a
Low dose group High dose group p value
800 IU/d 4,370 IU/d
N = 21 N = 24
Age (years) 44.7 ± 10.7 43.1 ± 12.3 0.7 b
43.6 (26.7-63.9) 43.1 (21.7-63.7)
Gender (Male/Female) F 13 (62%) F 19 (79%) 0.2 c
M 8 (38%) M 5 (21%)
Time from MS diagnosis (years) 9.3 ± 7.4 6 ± 5.7 0.08 d
8.1 (0.4-32.9) 3.4 (0.3-19.1)
IFN-β treatment duration (months) 61.3 ± 46 38.9 ± 32.5 0.1 d
59.1 (3.1-144.1) 23.4 (1.2-96.7)
EDSS 3.6 ± 2.2 2.9 ± 2.0 0.4 d
4.5 (0–7) 2.5 (0–7)
Patients with relapses during the year preceding randomization 6/21 (28.6%) 8/24 (33.3%) 0.7 c
Annualized relapse rate during the year preceding randomization 0.38 ± 0.26 0.28 ± 0.23 0.6 e

a. Summary statistics are mean ± standard deviation and median (range).

b. Student’s t-test.

c. Chi square test.

d. Mann–Whitney test.

e. Mid-P exact test.

Golan et al.

Golan et al. BMC Neurology 2013 13:60   doi:10.1186/1471-2377-13-60

Open Data